Leibman Financial Services Inc. Raises Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Leibman Financial Services Inc. increased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 27.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,637 shares of the company’s stock after acquiring an additional 6,805 shares during the quarter. Leibman Financial Services Inc.’s holdings in Progyny were worth $530,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in shares of Progyny by 299.2% in the 3rd quarter. SG Americas Securities LLC now owns 52,152 shares of the company’s stock valued at $874,000 after purchasing an additional 39,089 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Progyny during the 2nd quarter worth $44,000. Quarry LP grew its position in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after buying an additional 836 shares during the period. Creative Planning increased its stake in Progyny by 13.8% in the 2nd quarter. Creative Planning now owns 10,564 shares of the company’s stock valued at $302,000 after purchasing an additional 1,283 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN grew its holdings in Progyny by 1.8% in the second quarter. Disciplined Growth Investors Inc. MN now owns 528,412 shares of the company’s stock valued at $15,118,000 after purchasing an additional 9,358 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Up 1.4 %

Shares of NASDAQ:PGNY opened at $16.32 on Wednesday. The company has a market cap of $1.47 billion, a PE ratio of 26.75, a P/E/G ratio of 1.54 and a beta of 1.43. The firm has a 50-day simple moving average of $21.17 and a 200 day simple moving average of $26.92. Progyny, Inc. has a fifty-two week low of $13.93 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY) last released its earnings results on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The firm had revenue of $304.09 million for the quarter, compared to analysts’ expectations of $305.32 million. During the same quarter last year, the company earned $0.15 EPS. Progyny’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, research analysts forecast that Progyny, Inc. will post 0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

PGNY has been the topic of several research reports. JPMorgan Chase & Co. lowered their price target on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. Jefferies Financial Group dropped their price objective on shares of Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, September 19th. BTIG Research lowered Progyny from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. JMP Securities lowered Progyny from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 19th. Finally, Canaccord Genuity Group reduced their price objective on Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a research note on Friday, September 20th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $27.73.

Insider Buying and Selling at Progyny

In other news, President Michael E. Sturmer sold 9,030 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the sale, the president now owns 362,583 shares in the company, valued at $10,877,490. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.